SARS-CoV-2 COVID Vaccine Market Analysis & Forecast to 2026
This report provides a comprehensive overview of the size of the SARS-CoV-2 COVID Vaccine market, segmentation of the industry (by geography and vaccine technology), key players and the vast potential of vaccines that are in clinical trials. Kelly Scientific analysis indicates that the global COVID vaccine market was worth $59 billion in 2021. However, our forecast indicates that an initial drop will occur in 2022 due to a number of factors including single booster shots as opposed to two shot vaccines and reduced prices in vaccines due to competition. The COVID vaccine industry is expected to then grow significantly at a CAGR of over 9% and reach $47.5 billion by 2026. This is due to an opening up of the market from a closed government dominated space to one in which private healthcare providers and companies can purchase vaccines. There will also be a continued significant un-met need for vaccine boosters in an endemic situation.
This report describes the evolution of such a huge market in 8 chapters supported by over 74 tables and figures in over 137 pages. The report focuses on the following:
- An overview of the SARS-CoV2 virus that includes: genetic and structural analysis, mutation and variant characterization
- Global COVID vaccine market, global landscape analysis, vaccine technology breakdown and leading market players
- Advance purchase agreements, marketed/pipeline products, financial analysis and business strategy of the major companies in this space
- Focus on current trends, business environment, pipeline products, clinical trials, and future market forecast for COVID vaccines to 2026
- Clinical trial timelines for major vaccines in the pipeline
- Insight into the challenges faced by stakeholders, particularly manufacturers and governments
- Insight into the emergence of variants and their impact on vaccine effectiveness and the overall market
- Financial market forecast through 2026 with CAGR values of all market segments – vaccine technology, geography (US, EU, UK, Japan, RoW) and major players
- Influence of the molecular diagnostics, PCR testing and POC testing landscapes
- Numbers of vaccine doses available by each manufacturer per annum
- Geographical analysis and challenges within countries with respect to advance purchase agreements and distribution channels
- 1.0 Introduction
- 1.1 Emergence of SARS-CoV2 and the COVID Pandemic
- 1.2 SARS-CoV-2 Protein and RNA Structure
- 1.3 SARS-CoV-2 Infection and Immune Response
- 1.4 SARS-CoV-2 Mutations
- 1.4.1 B.1.1.7 Variant
- 1.4.2 B.1.351 Variant
- 1.4.3 P.1 Variant
- 1.4.4 Rapid Spread of D614G Mutation Globally
- 1.4.5 Variants and Vaccine Efficacy
- 1.4.6 BNT162b2 mRNA Covid-19 Vaccination Effectiveness in Israel
- 1.4.7 Challenges of Mid-Term and Long-Term Mutations
- 1.5 Future of Living Alongside SARS-CoV-2
- 2.0 COVID Vaccines
- 2.1 Introduction 2.1.1 mRNA Vaccines
- 2.1.2 DNA Vaccines
- 2.1.3 Inactivated Vaccines
- 2.1.4 Live-Attenuated Vaccines
- 2.1.5 Recombinant Protein Vaccines
- 2.1.6 Viral Vector Vaccines
- 2.2 Pfizer/BioNTech BNT162b2 Vaccine
- 2.3 Moderna mRNA1273 Vaccine
- 2.4 CureVac CVnCoV Vaccine
- 2.5 AstraZeneca/Oxford AZD-1222 Vaccine
- 2.6 Johnson & Johnson’s JNJ-78436735 Vaccine
- 2.7 Novavax NVX-CoV2373 Vaccine
- 2.8 Gamaleya Sputnik V Vaccine
- 2.9 Sinovac Coronavac Vaccin
- 3.0 Clinical Trials
- 3.1 Introduction
- 3.2 Clinical Trials by Geographic Area
- 3.3 Clinical Trials by Phase
- 3.3.1 Phase III COVID Vaccine Trials
- 3.3.2 Phase II COVID Vaccine Trials
- 3.3.3 Phase I COVID Vaccine Trials
- 4.0 Molecular Diagnostics & PCR Testing
- 4.1 Introduction
- 4.2 PCR Diagnostic Testing Has Dominated the Space
- 4.3 Point of Care Testing
- 5.0 Market & Industry Analysis
- 5.1 Advance Purchase Agreements by Company
- 5.1.1 Pfizer/BioNTech
- 5.1.2 Moderna
- 5.1.3 AstraZeneca/Oxford
- 5.1.4 Novavax
- 5.1.5 Sanofi/GSK
- 5.1.6 J&J
- 5.1.7 Curevac
- 5.2 Advance Purchase Agreements - Geographical Breakdown
- 5.2.1 USA
- 5.2.2 EU
- 5.2.2.1 Distribution of Vaccines within the EU
- 5.2.3 Japan
- 5.2.4 Australia
- 5.2.5 China
- 5.2.6 UK
- 5.2.7 Russia
- 5.3 Price of Vaccines
- 5.4 Reasons for Booster Vaccine Requirements
- 6.0 COVID Vaccine Pandemic Market Analysis 2021
- 6.1 Market Revenue, Volume and Major Players
- 6.2 SubMarket by Major Player Breakdown
- 6.3 SubMarket by Technology Type
- 6.4 SubMarket by Geographical Breakdown
- 7.0 COVID Vaccine Market 2022 to 2026
- 7.1 Endemic Market Forecast to 2026
- 7.2 SubMarket by Geographical Breakdown to 2026
- 7.3 SubMarket by Major Player Breakdown to 2026
- 7.4 SubMarket by Vaccine Technology Breakdown to 2026
- 8.0 Future Outlook
- List of Exhibits
- Exhibit 1 Coronavirus Protein and RNA Structure
- Exhibit 2 Common Symptoms Arising From SARS-CoV-2 Infection
- Exhibit 3 Lifecycle of SARS-CoV2
- Exhibit 4 Emergence of SARS-CoV-2 Mutations
- Exhibit 5 SARS-CoV-2 Mutations - Current Variants of Concern
- Exhibit 6 Emergence & Spread of SARS-CoV-2 Variants of Concern Globally
- Exhibit 7 Mutations in the B.1.1.7 SARS-CoV-2 Variant Genome
- Exhibit 8 Mutations in the B.1.351 SARS-CoV-2 Variant Genome
- Exhibit 9 Mutations in the P.1 SARS-CoV-2 Variant Genome
- Exhibit 10 Rapid Spread of D614G SARS-CoV-2 Variant over Time
- Exhibit 11 SARS-CoV-2 Variants and Vaccine Efficacy
- Exhibit 12 Neutralization of Variants B.1.1.7 and B.1.351 by Serum from mRNA-1273-Immunized Individuals
- Exhibit 13 Israel Vaccination Cumulative Incidence of Five Outcomes
- Exhibit 14 Israel COVID Vaccination Effectiveness during Three Time Periods
- Exhibit 15 COVID Vaccine Types by Technology Platform
- Exhibit 16 RNA Vaccine Technology, Benefits & Mechanism of Action
- Exhibit 17 Advantages of mRNA Vaccines
- Exhibit 18 Main COVID-19 Vaccines in the Market
- Exhibit 19 Pfizer/BioNTech BNT162b2 Clinical Trial Stats
- Exhibit 20 Moderna mRNA1273 Mechanism of Action
- Exhibit 21 Moderna mRNA-1273 R&D and Trial Timeline
- Exhibit 22 Moderna mRNA-1273 T Cell Immunogenicity Data
- Exhibit 23 Moderna Distribution Infrastructure of mRNA1273
- Exhibit 24 CureVac CVnCoV Vaccine Phase 1 Spike Binding Antibodies: Show Dose-Dependent Induction
- Exhibit 25 CureVac Strategy to Track SARS-CoV-2 Evolution and Occurrence of New Mutations
- Exhibit 26 CureVac CVnCoV Vaccine Shelf Life Allows for Established Cold-Chain Distribution
- Exhibit 27 AstraZeneca Vaccine Mechanism of Action Exhibit 28 Mechanism of Action of J&J’s COVID Vaccine
- Exhibit 29 Novavax NVX-CoV2373 Vaccine Technology
- Exhibit 30 Gamaleya’s Sputnik V Vaccine Double Adenoviral Vector Technology
- Exhibit 31 Gamaleya’s Sputnik V Vaccine Immune Response over Time
- Exhibit 32 Sinovac’s Coronavac Vaccine Technology
- Exhibit 33 Clinical Trial Timelines for Main COVID Vaccine Candidates
- Exhibit 34 Proportion of COVID Vaccines by Technology and Phase
- Exhibit 35 Global SARS-CoV-2 and Vaccine Clinical Trials by Region
- Exhibit 36 European SARS-CoV-2 and Vaccine Clinical Trials by Country
- Exhibit 37 SARS-CoV-2 and Vaccine Clinical Trials in the USA by State
- Exhibit 38 SARS-CoV-2 and Vaccine Clinical Trials in South America by Country
- Exhibit 39 Comparison of Main COVID Vaccines Either with Emergency Approval or in Late Stage Development
- Exhibit 40 Global SARS-CoV-2 and Vaccine Phase III Clinical Trials
- Exhibit 41 Select Phase III Clinical Trials by Vaccine Type
- Exhibit 42 Select Phase III Clinical Trials Investigating COVID Vaccines, Globally
- Exhibit 43 Selected Phase II COVID Vaccine Trials Globally
- Exhibit 44 Select Phase I Clinical Trials Investigating COVID Vaccines, Globally
- Exhibit 45 Daily COVID-19 Tests per Thousand People in Selected Countries Over Time
- Exhibit 46 USA Antigen and PCR Lab Based Test Volume in Millions, 2021
- Exhibit 47 USA Antigen and PCR Lab Based Test Volume in Millions, 2021
- Exhibit 48 USA Total Lab Based Test Volume in Millions, 2021
- Exhibit 49 USA Antigen and Molecular POC Test Volume in Millions, 2021
- Exhibit 50 USA Antigen, Molecular and Home POC Test Volume
- Exhibit 51 Total USA POC Testing Volume in Millions
- Exhibit 52 Vaccine Pre-Purchase Agreements by Country and Millions of the Population Covered
- Exhibit 53 European Commission 27 Member States
- Exhibit 54 Sputnik V Vaccine International Pre-Purchase Agreements by Country
- Exhibit 55 Vaccine Capacity and Pre-Orders by Company
- Exhibit 56 Vaccine Pre-Orders Country Dose number per Capita
- Exhibit 57 Price Differences of Vaccines by Manufacturer and Geographic Region
- Exhibit 58 Doses of COVID Vaccines Potentially Available in 2021 by Company in Billions
- Exhibit 59 COVID Vaccine Market in 2021 by Company Revenue
- Exhibit 60 COVID Vaccine Market in 2021 by Major Player Market Share
- Exhibit 61 COVID Vaccine SubMarket Share by Technology – Volume of Doses 2021
- Exhibit 62 COVID Vaccine SubMarket Share by Technology – Revenue (Billions) in 2021
- Exhibit 63 COVID Vaccine SubMarket Share by Technology – Revenue Market Share in 2021
- Exhibit 64 Comparison of COVID Vaccine Revenue from the EU, UK, USA and Japan by Major Company
- Exhibit 65 COVID Vaccine Revenue by Geographic Area 2021
- Exhibit 66 COVID Vaccine Revenue by Geographic Market Share 2021
- Exhibit 67 COVID Vaccine Revenue EU Market Share by Company 2021
- Exhibit 68 COVID Vaccine Revenue UK Market Share by Company 2021
- Exhibit 69 COVID Vaccine Revenue USA Market Share by Company 2021
- Exhibit 70 COVID Vaccine Revenue Japan Market Share by Company 2021 Exhibit 71 COVID Vaccine Market Revenue 2022-2026 Forecast
- Exhibit 72 COVID Vaccine Market Revenue 2022-2026 Forecast by Geography
- Exhibit 73 COVID Vaccine Market Revenue 2022-2026 Forecast by Major Player
- Exhibit 74 COVID Vaccine Market Revenue 2022-2026 Forecast by Vaccine Technology
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook